As compared to images on a conventional SPECT camera, stress myocardial perfusion images acquired on a CZT camera are more frequently interpreted as normal with identical clinical outcome after 1-year follow-up. This lowers the need for additional testing, results in lower mean radiation dose and shortens imaging time.

Also in CZT SPECT image quality decreases with weight. The use of a tracer dose and scan time that depends linearly on patient's body weight corrected for the varying image quality in CZT-SPECT MPI. This leads to better radiation exposure justification.

A major disadvantage of 18 F-FDG PET involves poor detection of small lesions and lesions with low metabolism, caused by limited spatial resolution and relatively large image voxel size. As spatial resolution and sensitivity are better in new PET systems, it is expected that small-lesion detection could be improved using smaller voxels. The aim of this study was to test this hypothesis using a state-of-the-art time-of-flight PET/CT device. Methods: 18 F-FDG PET scans of 2 image-quality phantoms (sphere sizes, 4-37 mm) and 39 consecutive patients with lung cancer were analyzed on a time-of-flight PET/CT system. Images were iteratively reconstructed with standard 4 · 4 · 4 mm voxels and smaller 2 · 2 · 2 mm voxels. For the phantom study, we determined contrast-recovery coefficients and signal-to-noise ratios (SNRs). For the patient study, 18 F-FDG PET-positive lesions in the chest and upper abdomen with a volume less than 3.0 mL (diameter, ,18 mm) were included. Lesion mean and maximum standardized uptake values (SUV mean and SUV max , respectively) were determined in both image sets. SNRs were determined by comparing SUV max and SUV mean with background noise levels. A subanalysis was performed for lesions less than 0.75 mL (diameter, ,11 mm). For qualitative analysis of patient data, 3 experienced nuclear medicine physicians gave their preference after visual side-by-side analysis. Results: For phantom spheres 13 mm or less, we found higher contrast-recovery coefficients and SNRs using small-voxel reconstructions. For 66 included 18 F-FDG PET-positive lesions, the average increase in SUV mean and SUV max using the small-voxel images was 17% and 32%, respectively (P , 0.01). For lesions less than 0.75 mL (21 in total), the average increase was 21% and 44%, respectively. Moreover, averaged over all lesions, the mean and maximum SNR increased by 20% and 27%, respectively (P , 0.01). For lesions less than 0.75 mL, these values increased up to 23% and 46%, respectively. The physicians preferred the small-voxel reconstructions in 76% of cases. Conclusion: Supported by a phantom study, there was a visual preference toward 18 F-FDG PET images reconstructed with 2 · 2 · 2 mm voxels and a profound increase in standardized uptake value and SNR for small lesions. Hence, it is expected that small-lesion detection improves using smallvoxel reconstructions. Whole-body 18 F-FDG PET integrated with CT is widely used for primary tumor analysis and mediastinal lymph node staging in patients with non-small cell and small cell lung cancer (1,2). For these patients, accurate lymph node staging is of high importance because both prognosis and therapeutic management depend on the tumor stage (3). A major disadvantage of 18 F-FDG PET involves poor detection of small lesions and lesions with low metabolism. With a sensitivity of 76% and specificity of 88% (4), PET/ CT is less sensitive for nodal involvement of small nodes (diameter, ,10 mm) (3,5). This poor detection is caused by limited spatial resolution and sensitivity (3,6). To impro...

No abstract

After orthotopic liver transplantation (OLT) bone mass rapidly declines and vertebral fracture rate increases. We studied bone loss and parameters of bone turnover in 53 consecutive patients. In an attempt to reduce bone loss the patients were prophylactically treated with cyclical etidronate in addition to daily 1 alpha-hydroxyvitamin D3 and calcium. During the first 3 months after transplantation median lumbar spinal bone mineral density (BMD) decreased 4.5%; subsequently no significant changes occurred. Median hip BMD continued to fall during the first post-transplantation year and deteriorated 7% over the whole study period. New vertebral fractures were seen in 25% of the patients, which is not lower than previously reported rates in patients not receiving cyclical etidronate. Parathyroid hormone levels increased after OLT (p = 0.01), but remained within normal ranges. Urinary hydroxyproline levels were increased and normalized in the second half-year after OLT. Elevated fasting calciuria increased further after OLT. 1,25-Dihydroxy-vitamin D3 levels were lowered pre-OLT (25 vs 66 pmol/ 1, p< 0.001) and normalized at 3 months after OLT. Serum osteocalcin concentrations remained unchanged and were reduced compared with levels in healthy controls. In summary, increased bone resorption occurs after OLT with persistent decreased bone formation, leading to vertebral fracture in 25% of patients. Etidronate, 1 alpha-calcidol and calcium treatment did not prevent bone loss.

The ALSYMPCA study established a 3.6 month Overall Survival (OS) benefit in metastatic Castration Resistant Prostate Cancer (mCRPC) patients treated with Radium‐223 dichloride (Ra‐223) over placebo. Here we report clinical outcomes of Ra‐223 treatment in a nonstudy population. In this prospective registry, patients from 20 Dutch hospitals were included prior to Ra‐223 treatment. Clinical parameters collected included previous treatments and Adverse Events. Primary outcome was 6 months Symptomatic Skeletal Event (SSE)‐free survival, while secondary outcomes included Progression‐Free Survival (PFS) and Overall Survival (OS). Of the 305 patients included, 300 were evaluable. The mean age was 73.6 years, 90% had ≥6 bone metastases and 74.1% were pretreated with Docetaxel, 19.5% with Cabazitaxel and 80.5% with Abiraterone and/or Enzalutamide. Of all patients, 96.7% were treated with Ra‐223 and received a median of 5 cycles. After a median follow‐up of 13.2 months, 6 months SSE‐free survival rate was 83%, median PFS was 5.1 months and median OS was 15.2 months. Six months SSE‐free survival rate and OS were comparable with those reported in ALSYMPCA. “Previous Cabazitaxel treatment” and “bone‐only metastases” were independent predictors of a shorter and longer PFS, respectively, while above‐median LDH and “bone‐only metastases” were independent predictors of shorter and longer OS, respectively. Toxicity was similar as reported in the ALSYMPCA trial. These results suggest that in a nonstudy population, Ra‐223 treatment is well‐tolerated, equally effective as in the ALSYMPCA population and that patients not previously treated with Cabazitaxel benefit most from Ra‐223.

A CAC score of zero in stable patients at low or intermediate risk excludes flow-limiting CAD. These findings support the possibility of CAC scoring as a simple and safe tool to select patients for additional testing or discharge, as recommended in the literature.

BackgroundThe decreasing image quality in heavier patients can be compensated by administration of a patient-specific dose in myocardial perfusion imaging (MPI) using a cadmium zinc telluride-based SPECT camera. Our aim was to determine if the same can be achieved when using a conventional SPECT camera.Methods148 patients underwent SPECT stress MPI using a fixed Tc-99m tetrofosmin tracer dose. Measured photon counts were normalized to administered tracer dose and scan time and were correlated with body weight, body mass index, and mass per length to find the best predicting parameter. From these data, a protocol to provide constant image quality was derived, and subsequently validated in 125 new patients.ResultsBody weight was found to be the best predicting parameter for image quality and was used to derive a new dose formula; Aadmin (MBq) = 223·body weight (kg)0.65/Tscan (min). The measured photon counts decreased in heavier patients when using a fixed dose (P < .01) but this was no longer observed after applying a body-weight-dependent protocol (P = .20).ConclusionsApplication of a patient-specific protocol resulted in an image quality less depending on patient’s weight. The results are most likely independent of the type of SPECT camera used, and, hence, adoption of patient-specific dose and scan time protocols is recommended.